Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial

Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial

Background A proposed cause of dyspnea induced by ticagrelor is an increase in adenosine blood levels. Because caffeine is an adenosine antagonist, it can potentially improve drug tolerability with regard to dyspnea. Furthermore, association between caffeine and cardiovascular events is of clinical...

Full description

Bibliographic Details
Main Authors: Remo H. M. Furtado, Ramkumar V. Venkateswaran, Jose C. Nicolau, Yared Gurmu, Deepak L. Bhatt, Robert F. Storey, P. Gabriel Steg, Giuglia Magnani, Shinya Goto, Mikael Dellborg, Gabriel Kamensky, Daniel Isaza, Philip Aylward, Per Johanson, Marc P. Bonaca
Format: Article
Language:English
Published: Wiley 2020-05-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
arrhythmias
caffeine
cardiovascular outcomes
dyspnea
ticagrelor
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.119.015785

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.119.015785

Similar Items